Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558231 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
A Phase 3 study of Pulmonary Arterial Hypertension, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
- 20
- Study locations
NCT02558231: Completed Phase 3 study of Pulmonary Arterial Hypertension, sponsored by Actelion.
NCT02558231 is a Phase 3 study of Pulmonary Arterial Hypertension that has completed, run by Actelion. The registered enrollment target is 247 participants, below the 458-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02558231, a Phase 3 study of Pulmonary Arterial Hypertension, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.
Primary Outcome
Change from baseline to Week 26 in PVR was expressed as the ratio of Week 26 to baseline PVR value (Week 26 divided by baseline) using re-calculated PVR. PVR was determined by right heart catheterization (RHC). A geometric least square mean ratio of Week 26 to baseline PVR less than (\<) 1 corresponds to a reduction in PVR from baseline. Missing values were imputed using a last observation carried forward (LOCF) approach.
Conditions Studied
Interventions
- DRUG Tadalafil
- DRUG Selexipag
- DRUG Macitentan
Study Locations (20)
California
- UCSD Health Sciences - La Jolla
- UCLA Medical Center - Los Angeles
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Cleveland Clinic Florida - Weston
Massachusetts
- Tufts Medical Center - Boston
- Boston University Medical Center - Boston
Pennsylvania
- Allegheny General Hospital of Research - Pittsburgh
- UPMC Presbyterian - Pittsburgh
Texas
- University of Texas Southwestern Medical Center - Dallas
- Houston Methodist Hospital - Houston
Arizona
- Arizona Pulmonary Specialists, LTD - Phoenix
Georgia
- Piedmont Pulmonary and Critical Care Research - Atlanta
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2020-04-20 |
| Phase | Phase 3 |
What the finished NCT02558231 record still lists
NCT02558231 is an interventional study that assigns participants to a tested intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap, below the 458-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Tadalafil is the first listed.
NCT02558231 names 20 study sites across 15 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02558231 about?
NCT02558231 is a clinical study titled "The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension". The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arteria...
What is the current status of trial NCT02558231?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2016-05-01. Estimated completion is 2020-04-20.
What conditions does trial NCT02558231 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT02558231?
The interventions under investigation include: Tadalafil (DRUG), Selexipag (DRUG), Macitentan (DRUG).
Who is sponsoring clinical trial NCT02558231?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02558231 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02558231's enrollment target sits among peer trials
247 13th of 63 higher than 51 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
RECRUITING · Phase 3
-
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
ACTIVE NOT RECRUITING · Phase 3
-
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 3
-
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI